British cost agency to take broader view of drug value

By Ben Hirschler LONDON (Reuters) – British healthcare cost agency NICE is to take a broader view of the value offered by new medicines under proposals that may make it more likely that it will say “yes” to novel drugs in future. Chief Executive Andrew Dillon told Reuters that wider uptake would only occur, however, if pharmaceutical manufacturers kept a tight rein on prices. The National Institute for Health and Clinical Excellence (NICE), which determines the use of treatments on the state-run health service, will in future look at the “wider societal impact” of therapies, as well as their cost-effectiveness on more limited clinical grounds.